PMID: 2123013Dec 19, 1990Paper

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

JAMA : the Journal of the American Medical Association
K A SchulmanJ M Eisenberg

Abstract

We performed a cost-effectiveness analysis of pharmacologic treatment of high blood cholesterol levels. Agents modeled were cholestyramine, colestipol, gemfibrozil, lovastatin, niacin, and probucol. Pharmacologic effectiveness was estimated from reported studies. Cost estimates reflect societal resource consumption. Annual costs for therapy ranged from $327 (niacin) to $1881 (lovastatin, 80 mg/d). Niacin was the most efficient agent for reducing low-density lipoprotein cholesterol levels, having an average cost over 5 years of $139 per percent reduction in low-density lipoprotein cholesterol level. Lovastatin (20 mg/d) was also efficient ($177 per percent reduction). Cholestyramine was least efficient at $347. For high-density lipoprotein cholesterol, niacin was most efficient, at $116 per percent increase in high-density lipoprotein cholesterol level, followed by gemfibrozil at $271. Analyses combining low-density lipoprotein cholesterol and high-density lipoprotein cholesterol effects suggest that niacin and lovastatin (20 mg/d) were most efficient for reducing cardiovascular risk.

Citations

May 1, 1991·Journal of General Internal Medicine
May 13, 1999·Journal of Epidemiology and Community Health·T van der WeijdenR P Grol
Oct 20, 2005·Journal of Epidemiology and Community Health·Oscar H FrancoLuc Bonneux
Mar 9, 2010·Journal of the American Board of Family Medicine : JABFM·Paul WintersKevin Fiscella
Jun 24, 2004·Current Treatment Options in Cardiovascular Medicine·William S. Weintraub
Jun 28, 2008·Current Treatment Options in Cardiovascular Medicine·Nerses Sanossian, Nicholas E Tarlov
Sep 29, 2001·Journal of Clinical Epidemiology·L LalondeUNKNOWN Canadian Collaborative Cardiac Assessment Group
Feb 4, 2003·Current Atherosclerosis Reports·Dean G Smith
Oct 1, 1999·Environmental Health and Preventive Medicine·N NakanishiK Tatara
Feb 1, 1996·Cardiology Clinics·T A Pearson, H J Swan
May 1, 1995·Journal of Vascular and Interventional Radiology : JVIR·D Yin, H P Forman
Jul 15, 1994·The American Journal of Cardiology·T A JacobsonL F Amorosa
Jan 1, 1992·Clinical and Experimental Hypertension. Part A, Theory and Practice·N M Kaplan
Apr 22, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Amy K O'SullivanMichael F Drummond
May 6, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·J W Hay, J S Schwartz
May 6, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·T E Delea
Jul 11, 1998·Journal of Biomaterials Science. Polymer Edition·M NichiforA Carpov
Apr 18, 1992·BMJ : British Medical Journal·J F Goodwin, I Sharp
Apr 27, 1991·BMJ : British Medical Journal·B R Birch
Apr 27, 1991·BMJ : British Medical Journal·M A Zuckerman, J S Oxford
Apr 27, 1991·BMJ : British Medical Journal·D P GrayP Evans
Feb 27, 1993·BMJ : British Medical Journal·J MasonG Torrance

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.